La recherche de la Fondation Jérôme Lejeune

Apply for a Grant

Apply for a Grant

The main target of the Jerome Lejeune Foundation, a non-profit foundation, is research into genetic diseases with intellectual disability.

If you are a researcher investigating on Down syndrome and other intellectual disability from genetic origin appearing in early childhood, the Scientific Advisory Board of the Jerome Lejeune Foundation invites you to submit your research project aiming at deciphering the pathophysiology of the cognitive deficits of patients, especially those (up to 50% of the total amount of the global grant) with Down syndrome (trisomy 21) and linked pathologies as well as knowledge of the chromosome 21.

The calls for proposals have been changed!

The current Autumn call for proposals will be exclusively dedicated to Down syndrome research with Advanced and Pilot/exploratory grants.

Spring call for proposals (from mid-January to early March) will be dedicated to both Down syndrome and other rare intellectual disabilities from genetic origin such as Fragile X, cri du chat, Rett, Williams-Beuren, Prader-Willi, Angelman, Smith-Magenis and other syndromes, and will not exceed 50% of the total amount of the annual global grant. Autism not linked to above diseases is out of this call for grants.

Applications could cover fundamental, translational, epidemiological, clinical research, neurobiology, and pharmacology including animal pharmacology, genetic, genomic, iPSCs, and neuropsychology techniques or data analysis. Priority will be given to clinical research projects.

Two types of research projects may be submitted and will be separately evaluated by the scientific board experts or external reviewers if needed for each call:

  • Advanced grants will be dedicated to larger breakthrough projects with preliminary data. The maximum funding will be 80,000.00 € for a maximum of two years (i.e. 40,000.00 € per year for a maximum of two years). Ideally, two to four projects could be funded per call, but it could be more or less.
  • Pilot or exploratory grants will be dedicated to initial early stage experiments built on preliminary data, or to ancillary projects to primary larger projects. The maximum funding will be 40,000.00 € for a maximum of two years (i.e. 20,000.00 € per year for a maximum of two years. The number of funded projects will depend of the annual global budget allocated by the Jerome Lejeune Foundation to the calls. Clinical projects could benefit from more funding.
  • Through this call the Jerome Lejeune Foundation will also support the organization of conferences, workshops and courses. Such projects will also be reviewed by the Scientific Advisory Board.

IMPORTANT: The funds provided by the Jerome Lejeune Foundation cannot in any way be used to purchase or make use of human embryonic or fetal tissues or another biological material obtained through direct abortions, IVF or human cloning or to  create new human  germinal cells. The Jerome Lejeune Foundation does not agree to be associated with such a work.

The researchers should mandatory follow their academic and national Good Laboratory Practices (GLP) (i.e. all measures that ensure, during the all research, quality, traceability and integrity of the data.).

PRACTICAL INFORMATION

For this Autumn call for proposals, please fill in the online application form on “JLF Call for grants” from 22 June to 10 August 2020 at midnight.

Before applying, please read the restrictions linked to the General Data Protection Regulation (GDPR/RGPD). For any request regarding the processing of your personal data, please contact us at the following email address: dpo@institutlejeune.org

But for any further information relating specifically to the call for grants, please contact:

Fondation Jérôme Lejeune – Conseil Scientifique
37 rue des Volontaires, 75015 Paris
conseilscientifique@fondationlejeune.org
+33 (0)1 5658 5638

Date of provisional Scientific Advisory Board decision: mid-November 2020

Board of Directors final decision: December 2020

 

 

Les projets subventionnés par la Fondation Jérôme Lejeune

Session 2017b

15 projets subventionnés par la Fondation Jérôme Lejeune pour un montant de 510 513 €

France : 4 ; Italie : 5 ; Espagne : 1 ; Israël : 1 ; Royaume-Uni : 2 ; Etats-Unis : 2

Projets portant sur la Trisomie 21

• Prof. Alberto Costa
Preclinical assessment of short-term sensory memory deficits in mouse models of Down syndrome: evaluation of a mismatch negativity paradigm
The Research Institute for Children’s Health (RICH)
Case Western Reserve School of Medicine
Cleveland (Ohio), USA

• Dr. JM Delabar
Etude de l’efficacité d’un analogue de l’EGCG dans des modèles murins de trisomie 21
Institut du Cerveau et de la Moelle (Brain & Spine Institute)
CNRS UMR 7225, INSERM U1127, UPMC
France

• Dr. Sandra Guidi
Prenatal treatment with a BDNF mimetic: a potential strategy for improving brain development in the Ts65Dn mouse model of Down syndrome
University of Bologna
Department of Biomedical and Neuromotor Sciences (DIBINEM)
Italy

• Dr. Fernando Moldenhauer
Study of the renin-angiotensin-aldosterone system and its relation to the absence of atherosclerosis in adults with Down syndrome
Fundación de Investigació Biomédica Hospital de La Princesa
Unidad de Atención a Adultos con Sindrome de Down (MIH-UPDOWN)
Madrid, Spain

• Prof. Lucio Nitsch
Therapeutic approach in Down syndrome by PGC-1alpha activation in differentiating neural cells
University of Naples Federico II
Laboratory of Cytogenetics and Cytogenomics
Department of Molecular Medicine and Medical Biotechnology
Italy

• Dr. Nicoletta Pedemonte
A drug repositioning approach for the discovery of DYRK1A regulators as a therapy for Down syndrome
Istituto di Ricovero e Cura a Carattere Scientifico « Giannina Gaslini »
Genova, Italy

• Prof. Mary Rutherford
Serial MRI to assess early structural and functional brain development in Down syndrome
Centre for Developing Brain
Department of Perinatal Imaging and Health
Kings’ College London, United-Kingdom

 

Autres pathologies (syndromes tels que l’X fragile; Williams-Beuren; DiGeorge; Cri du chat…)

• Prof. Lior Appelbaum
The Allan-Herndon-Dudley syndrome: Visualizing deficient neuronal activity and examination of therapeutic applications
Bar Ilan University
Faculty of Life Sciences
Multidisciplinary Brain Research Center
Ramat Gan, Israel

• Dr. J.-V. Barnier
Caractérisation d’une nouvelle mutation d’un gène de déficience intellectuelle dans des anomalies neurodéveloppementales
Institut de Neuroscience Paris-Saclay, France

• Dr. Régine Hepp
Molecular mechanisms of a disease-causing missense mutation in the GRID1 gene associated with autosomal recessive intellectual disability
Université Pierre et Marie Curie
Institut de Biologie Paris-Seine
CNRS UMR8246/Inserm U1130/UPMC UMCR18
Paris, France

• Prof. Elizabeth Illingworth
Vitamin B12 treatment of mouse models of DiGeorge syndrome: is it effective for the brain phenotype?
Universita’ degli Studi di Salerno
Dipartimento di Chimica e Biologia
Fisciano, Italy

• Dr. Seonil Kim
Treatment of mental retardation and autistic-like characteristics in Cri du chat syndrome arising from delta-catenin haploinsufficiency
Colorado State University
Department of Biomedical Sciences
Fort Collins, USA

• Dr. Natacha Lehman
Thérapie Cognitive et Comportementale de l’anxiété dans le syndrome de Williams-Beuren
CHU Montpellier
France

• Dr. Viviana Trezza
The endocannabinoid system as a novel therapeutic target for Fragile X syndrome
Roma Tre University
Department of Science
Roma, Italy

• Dr. Jane Waite
Ten-year longitudinal follow-up of people with Rubinstein-Taybi syndrome: Predicting Mental Health outcomes
Aston University
School of Life and Health Sciences
Birmingham, United-Kingdom

Session 2018a

17 projets subventionnés par la Fondation Jérôme Lejeune pour un montant de 536 310 €

France : 7 ; Italie : 3 ; Espagne : 2 ; Belgique : 1 ; Israël : 1 ; Royaume-Uni : 1 ; Etats-Unis : 2

Pour information : les titres des projets ci-après ne préjugent en rien du champ d’application

Projets portant sur la Trisomie 21

• Dr. Juliette GODIN
Analysis of contribution of Wdr4, a critical gene located in Abcg1-U2af1 region, to the neurodevelopmental abnormalities of Down syndrome
Institut de génétique et de biologie moléculaire et cellulaire (IGBMC)
Laboratoire de Médecine translationnelle et neurogénétique
67 Illkirch, France

• Dr. Valldeflors VINUELA-NAVARRO
Investigating ocular morphological differences as the possible cause of accommodation deficits in
Down’s syndrome
Aston University
Ophthalmic Research Group
School of Life and Health Sciences
Birmingham, Royaume-Uni

• Dr. Vincent CAVAILLES
Trisomie 21 et Leucémies Aigües Myéloïdes: Rôle du facteur de transcription RIP140
Institut de Recherche en Cancérologie de Montpellier (IRCM)
INSERM U1194
34 Montpellier, France

• Dr. Jamie EDGIN
Sleep as a predictor of memory performance and stability in ID syndromes
University of Arizona
Down Syndrome Research Group (DSRG)
Department of Psychology
Tucson, AZ, Etats-Unis

• Dr. Angela LUKOWSKI
Examining recall memory and generalization in children with Down syndrome and neurotypical controls matched on developmental age
University of California, Irvine
Department of Psychology and Social Behavior
Irvine, CA, Etats-Unis

• Dr. Paloma APARICIO
Patterns and causes of hospital admission, comorbidities and mortality of Spanish adults with
Down syndrome 2005 – 2014
Hôpital Universitaire “La Princesa”
Unité pour les adultes atteints de Trisomie 21
Madrid, Espagne

• Prof. Greetje VANDE VELDE
Understanding Down syndrome as a neuro-skeletal disorder: towards integrated treatment of brain, bones and cognition
Université de Louvain
Département d’Imagerie et d’Anatomo-pathologie
Faculté de Médecine
Louvain, Belgique

• Dr. Javier ZORRILLA DE SAN MARTIN
Dendritic inhibition in animal models of cognitive disabilities
Institut du Cerveau et de la Moelle Epinière
75013 Paris, France

 

Autres pathologies (syndromes tels que l’X fragile; Williams-Beuren; DiGeorge; Cri du chat…)

• Dr. Victoria CAMPUZANO
Molecular bases in the effectiveness of the treatment of Williams-Beuren syndrome by inhibitors of the monoacyl glycerol lipase.
Universitat Pompeu Fabra
Genetic Unit
Barcelone, Espagne

• Pr. Rina ROSIN-ARBESFELD
Macrolide induced correction of mutations causing Rett syndrome (RTT)
Tel Aviv University
Department of Clinical Microbiology and Immunology
Tel Aviv, Israël

• Dr. Barbara BARDONI
Definition of a novel therapeutic approach for Fragile X syndrome
Institut de Pharmacie Moléculaire et Cellulaire (IPMC)
CNRS UMR 7275 – UNS
06 Valbonne, France

• Dr. Stéphane MARTIN
Consequences of the missense R138Q Fragile X mutation on the regulation of the FMRP function
Institut de Pharmacie Moléculaire et Cellulaire (IPMC)
CNRS UMR 7275 – UNS
06 Valbonne, France

• Dr. Patrizia D’ADAMO
Direct and indirect drugs modulation of Rab39b mutant mice-related behavioral deficits
Fondazione Centro San Raffaele at Ospedale San Raffaele
Division of Neuroscience
Milan, Italie

• Dr. Françoise MUSCATELLI
Critical timing of oxytocin treatment
Institut de Neurobiologie de la Méditerranée (INMED)
INSERM U901
13 Marseille, France

• Dr. Elisabetta CIANI
Innovative strategy to enhance the efficiency of brain gene therapy for the CDKL5 neurodevelopmental disorder
University of Bologna
Department of Biomedical and Neuromotor Sciences
Bologne, Italie

• Dr. Jessica ROSATI
The roles of biological clock deregulation and retinoic acid signalling impairment in Smith-Magenis syndrome
Casa Sollievo della Sofferenza – Mendel Institute
Cellular Reprogramming Unit
San Giovanni Rotondo, Foggia, Italie

• Dr. Aloïse MABONDZO
Congenital cREatine transporter Disorder: Insights into new Therapeutic preclinical strategies
CEA, Service de Pharmacologie et d’Immunoanalyse
91 Gif-sur-Yvette, France

Session 2018b

7 projets subventionnés par la Fondation Jérôme Lejeune pour un montant de 455 474 €

France : 1 ; Espagne : 3 ; Australie : 2 ; Etats-Unis : 1

Pour information : les titres des projets ci-après ne préjugent en rien du champ d’application

Session exclusivement dédiée aux projets portant sur la Trisomie 21

• Dr. Maria Victoria PUIG VELASCO
Neural activity patterns underlying cognitive normalization by EGCG and GABAa( α5IA in the Ts65Dn mouse model of Down syndrome
IMIM – Hospital del Mar Medical Research Institute
Department of Integrated Pharmacology and Systems Neuroscience
Barcelone, Espagne

• Pr. Maria del Mar DIERSSEN SOTOS
As president of the T21 Research Society
3rd International Meeting of the Trisomy 21 Research Society
Centre for Genomic Regulation (CRG)
Barcelone, Espagne

• Dr. Sandra GIMENEZ BADIA
The impact of Alzheimer’s disease on sleep in adults with Down syndrome
Hospital de la Santa Creu and Sant Pau, Institut d’Investigacio Biomèdica Sant Pau
Barcelone, Espagne

• Pr. Rosemary HORNE
Optimising daytime and cardiovascular function in children with Down syndrome through treatment of Obstructive Sleep Apnoea
Monash University and Hudson Institute of Medical Research
Department of Pediatrics
Melbourne, Australie

• Dr. Charles HOEFFER
RCAN1, synaptic plasticity, and neuronal phosphatase dysregulation in Down syndrome
University of Colorado
Institute for Behavioral Genetics
Boulder, Colorado, Etats-Unis

• Dr. Sébastien MALINGE
Targeting DYRK1A: a key player in Down syndrome Leukaemogenesis
University of Western Australia
Telethon Kids Institute – Cancer Centre
Nedlands, Australie

• Dr. Olivier MASCARO
The neurocognitive bases of trust in Down syndrome: Affective evaluation, trait attribution, and epistemic vigilance
Institut des Sciences Cognitives
CNRS UMR5304
69 Bron, France